Investment Secured for Edinburgh Molecular Imaging
News Feb 10, 2014
Scottish Enterprise's investment arm, the Scottish Investment Bank, also provided funding. EMI, an Edinburgh BioQuarter spin-out company from the University of Edinburgh, is developing a pioneering Optical Molecular Imaging (OMI) technology with the potential to address unmet needs in the diagnosis and monitoring of several major diseases.
EMI is based upon the world‐class translational research (spanning chemistry, biology, and medicine) of its three founders from the University of Edinburgh:Professor Mark Bradley (School of Chemistry), Professor Chris Haslett and Dr Kev Dhaliwal (College of Medicine and Veterinary Medicine).
EMI's highly innovative OMI technology revolves around the development of fluorescent imaging reagents that detect harmful processes deep inside the human body, at the bedside, in real time and at molecular resolution. The company's initial focus is on lung conditions but the technology is applicable to a wide spectrum of disease.
The company's approach has the potential to transform clinicians' ability to diagnose and manage a number of serious respiratory conditions, including lung cancer, fibrosis, lung infections and acute respiratory distress syndrome (ARDS). EMI's technology will address the pressing need for tests which can rapidly provide diagnostic certainty and reduce healthcare costs. Respiratory diseases kill one in five people in the UK and cost the NHS over £6 billion per year, with lung cancer being the biggest cancer killer.
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
12th Edition of International Conference on Infectious Diseases
Apr 22 - Apr 23, 2019